Alimera Sciences To Hold Conference Call To Discuss First Quarter 2010 Financial Results
ATLANTA, May 26, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its first quarter 2010 financial results will be released after the market close on Thursday, June 3, and will be followed by an investor conference call on the same day at 4:30 p.m. ET.
The conference call will be hosted by Dan Myers, President and Chief Executive Officer, and Rick Eiswirth, Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (USA) or (253) 237-1165 (International). To access the live webcast, please visit the Investor Relations section on the corporate web site at http://www.alimerasciences.com.A replay of the conference call will be available beginning June 3, 2010 at 7:30 p.m. ET and ending on July 3, 2010 by dialing (800) 642-1687 (USA) or (706) 645-9291 (International), Conference ID Number: 76977260. A replay of the webcast will also be available on the corporate website for one month, through July 3, 2010. About Alimera Sciences, Inc. Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate Iluvien® is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
CONTACT: ICR, LLC For Alimera Sciences Donald Ellis 925-253-1240 Donald.Ellis@icrinc.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV